Last Updated: September 28, 2026

Allergan Company Profile

✉ Email this page to a colleague

What is the competitive landscape for ALLERGAN

ALLERGAN has sixty-five approved drugs.

Summary for Allergan

US Patents:	0
Tradenames:	61
Ingredients:	47
NDAs:	65
Patent Litigation for Allergan:	See patent lawsuits for Allergan
PTAB Cases with Allergan as patent owner:	See PTAB cases with Allergan as patent owner

Drugs and US Patents for Allergan

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Herbert	PENECORT	hydrocortisone	SOLUTION;TOPICAL	088214-001	Jun 6, 1984		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Allergan	TRIVARIS	triamcinolone acetonide	INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL	022220-001	Jun 16, 2008		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Allergan	FML	fluorometholone	OINTMENT;OPHTHALMIC	017760-001	Sep 4, 1985		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Allergan

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-001	Jul 3, 1996	5,202,128	⤷ Start Trial
Allergan	BETAGAN	levobunolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019219-002	Dec 19, 1985	3,641,152	⤷ Start Trial
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	3,419,578	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ALLERGAN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Transdermal System Extended-re	3.9 mg/24 hrs	➤ Subscribe	2008-08-19
➤ Subscribe	Ophthalmic Solution	0.30%	➤ Subscribe	2007-07-19
➤ Subscribe	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	➤ Subscribe	2011-12-19
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2009-03-02
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2008-10-14

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.